Autres langues Oncolytics Biotech Inc.

Actions

ONC

CA6823108759

Marché Fermé - Toronto S.E. Autres places de cotation 21:59:44 31/05/2024			Varia. 5j.	Varia. 1 janv.
1,46 ^CAD	-0,68 %		-2,01 %	-18,44 %

24/05	Oncolytics Biotech Inc. présente deux résumés à la réunion annuelle 2024 de la Société américaine d'oncologie clinique	CI
15/05	Transcript : Oncolytics Biotech Inc. - Shareholder/Analyst Call

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Oncolytics Biotech Inc. Presents Two Abstracts At the 2024 American Society of Clinical Oncology Annual Meeting	24/05
Transcript : Oncolytics Biotech Inc. - Shareholder/Analyst Call	15/05
Oncolytics Biotech® Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial	15/05
Oncolytics Biotech Announces Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial	15/05
RBC on Oncolytics Biotech's Upcoming Type C Meeting With FDA	13/05
Oncolytics Biotech Reports a First-Quarter Loss of Near $7 Million	09/05
Transcript : Oncolytics Biotech Inc., Q1 2024 Earnings Call, May 09, 2024	09/05
Oncolytics Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Oncolytics Biotech® Inc. Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX+/- an Anti-PD-L1 Inhibitor in Pancreatic Cancer	09/05
Oncolytics Biotech Inc. Announces the Submission of a Type C Meeting Request to the FDA	11/04
RBC Reiterates Positive Outlook For Oncolytics -- Maintains $6 Target, Outperform/Speculative Risk Rating	08/03
Transcript : Oncolytics Biotech Inc., Q4 2023 Earnings Call, Mar 07, 2024	07/03
Oncolytics Biotech Up 2.9% as Its Fourth-Quarter Loss Narrows on a One-Time Gain	07/03
Oncolytics Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Oncolytics Biotech Inc. Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN	05/03
Oncolytics Biotech Initiates Enrollment Expansion of GOBLET Anal Cancer Cohort	14/02
Oncolytics Biotech Inc. Appoints Patricia S. Andrews to Its Board of Directors	09/01
Oncolytics Biotech Provides Outlook for 2024	04/01
ONCOLYTICS BIOTECH INC. : HC Wainwright optimiste sur le dossier	13/11
Oncolytics Says Anal Cancer Cohort Of GOBLET Phase 1/2 Study Meets "Criteria For Efficacy"; Provides Update on Pancreatic Cancer Program	09/11

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Oncolytics Biotech Inc.

Actions

ONC

CA6823108759

Autres langues

Filtres